These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 25378751)
21. The role of emerging manufacturers in access to innovative vaccines of public health importance. Milstien JB; Kaddar M Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054 [TBL] [Abstract][Full Text] [Related]
22. Vaccines as a global imperative--a business perspective. Stéphenne J Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955 [TBL] [Abstract][Full Text] [Related]
23. Vaccine and vaccination. Ghosh AK J Indian Med Assoc; 1982 Apr; 78(8):141-2. PubMed ID: 7130727 [No Abstract] [Full Text] [Related]
24. Desirable attributes of vaccines for deployment in low-resource settings. Chen D; Zehrung D J Pharm Sci; 2013 Jan; 102(1):29-33. PubMed ID: 23136115 [TBL] [Abstract][Full Text] [Related]
28. Vaccine production in Russia: an update. Westerdahl KS; Roffey R Nat Med; 1998 May; 4(5 Suppl):506. PubMed ID: 9585200 [No Abstract] [Full Text] [Related]
29. Vaccine supply chains need to be better funded and strengthened, or lives will be at risk. Kaufmann JR; Miller R; Cheyne J Health Aff (Millwood); 2011 Jun; 30(6):1113-21. PubMed ID: 21653965 [TBL] [Abstract][Full Text] [Related]
30. [Vaccines and developing countries]. Bjune G Tidsskr Nor Laegeforen; 1991 May; 111(12):1496-9. PubMed ID: 2042182 [TBL] [Abstract][Full Text] [Related]
31. The need for quality control in the developing countries. Perkins FT Dev Biol Stand; 1978; 41():291-4. PubMed ID: 753657 [TBL] [Abstract][Full Text] [Related]
32. Reaching international GMP standards for vaccine production: challenges for developing countries. Milstien J; Costa A; Jadhav S; Dhere R Expert Rev Vaccines; 2009 May; 8(5):559-66. PubMed ID: 19397413 [TBL] [Abstract][Full Text] [Related]
33. Health care: Strict vaccine quality control in China. Liang Z; Mao Q; Wang J Nature; 2014 May; 509(7501):427. PubMed ID: 24848052 [No Abstract] [Full Text] [Related]
34. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Jadhav S; Datla M; Kreeftenberg H; Hendriks J Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742 [TBL] [Abstract][Full Text] [Related]
35. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices. Jadhav S; Gautam M; Gairola S Clin Microbiol Infect; 2014 May; 20 Suppl 5():37-44. PubMed ID: 24476201 [TBL] [Abstract][Full Text] [Related]
36. Global health and the Bill & Melinda Gates Foundation. Dabade G; Puliyel J Lancet; 2009 Jun; 373(9682):2195-6. PubMed ID: 19560591 [No Abstract] [Full Text] [Related]
37. Global Advisory Committee on Vaccine Safety, 11-12 June 2003. Wkly Epidemiol Rec; 2003 Aug; 78(32):282-4. PubMed ID: 15581216 [No Abstract] [Full Text] [Related]
38. Vaccine supply: a cross-national perspective. Danzon PM; Pereira NS; Tejwani SS Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165 [TBL] [Abstract][Full Text] [Related]
39. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers. Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398 [TBL] [Abstract][Full Text] [Related]